Anika Therapeutics | Capital Ordinário





Capital Ordinário Alterar Data
Abbott USD 1.74B 23.39B 2025-09
Agenus USD 266K 30K 2025-03
Agios Pharmaceuticals USD 58.28M 241K 2025-09
Anika Therapeutics USD 143K 1000 2025-03
Arrowhead Research USD 135.7M 2.44M 2025-09
Enanta Pharmaceuticals USD 212K 1000 2023-12
Halozyme Therapeutics USD 117.52M 98K 2025-09
Heron Therapeutics USD 1.52M 14K 2024-09
Insmed USD 212.58M 210.76M 2025-09
Integra LifeSciences USD 77.92M 77M 2025-06
Intrexon USD 0 0 2024-06
J&J USD 2.41B 584K 2025-09
Karyopharm Therapeutics USD 13K 0 2024-09
Ligand Pharmaceuticals USD 20K 0 2025-03
MacroGenics USD 63.26M 62.63M 2025-09
Merit Medical Systems USD 59.29M 72K 2025-09
Rigel Pharmaceuticals USD 17K 158K 2024-06
Smith & Nephew USD 875.96M 1.61M 2025-12
Stryker USD 382.4M 93K 2025-12
Surmodics USD 716K 4K 2024-09
Veracyte USD 78.67M 73K 2025-09
Xencor USD 71.34M 46K 2025-09
Zimmer Biomet Holdings USD 198.18M 18.44K 2025-12


Anika Therapeutics Capital Ordinário - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Feb 2026.